The Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL) North American Rare Disease Clinical Research Consortium: Progress and Characterization of Initial Participants (S49.002)

Conclusions:ARTFL is actively enrolling participants across North America to characterize sporadic and familial FTLD. Clinical, biomarker, genetic and imaging data from ARTFL and LEFFTDS will soon be available to investigators worldwide.Study Supported by: NINDS and NCATS U54NS092089 through the Rare Disease Clinical Research NetworkDisclosure: Dr. Boxer has received personal compensation for activities with Abbvie, Asceneuron, Janssen, Merck for consulting. Dr. Rosen has nothing to disclose. Dr. Boeve has received research support from GE Healthcare, FORUM Pharmaceuticals, C2N Diagnostics and Axovant. Dr. Heuer has nothing to disclose. Dr. Coppola has nothing to disclose. Dr. Dickerson has received personal compensation for activities with Merck as a consultant. Dr. Dickerson has received personal compensation in an editorial capacity for Neuroimage: clinical. Dr. Bordelon has received personal compensation for activities with Teva Pharmaceuticals, Lundbeck Inc, and Journal Watch for article review as a speaker, member of the scientific advisoary board or speakers bureau or article review. Dr. Conwit has nothing to disclose. Dr. Dheel has nothing to disclose. Dr. Faber has nothing to disclose. Dr. Feldman has received personal compensation for activities with Merck, Eli Lilly and Arena through UBC service agreements as a consultative. Dr. Feldman has also served as a member of safety and diagnostic monitoring committees for Eisai and Genentech Banner. Dr. Fields has nothing ...
Source: Neurology - Category: Neurology Authors: Tags: Best Of: Aging and Dementia Source Type: research